Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - CTI BIOPHARMA CORP | Financial_Report.xls |
| EX-10.3 - FORM OF EQUITY/LONG-TERM INCENTIVE AWARD AGREEMENT FOR THE EXECUTIVE OFFICERS - CTI BIOPHARMA CORP | d321569dex103.htm |
| EX-31.2 - SECTION 302 CFO CERTIFICATION - CTI BIOPHARMA CORP | d321569dex312.htm |
| EX-31.1 - SECTION 302 CEO CERTIFICATION - CTI BIOPHARMA CORP | d321569dex311.htm |
| 10-Q - FORM 10-Q - CTI BIOPHARMA CORP | d321569d10q.htm |
| EX-10.4 - FORM OF EQUITY/LONG-TERM INCENTIVE AWARD AGREEMENT FOR THE DIRECTORS - CTI BIOPHARMA CORP | d321569dex104.htm |
Exhibit 32
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, James A. Bianco, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of Cell Therapeutics, Inc., that, to my knowledge, the Quarterly Report of Cell Therapeutics, Inc. on Form 10-Q for the fiscal quarter ended March 31, 2012 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Cell Therapeutics, Inc.
A signed original of this written statement required by Section 906 has been provided to Cell Therapeutics, Inc. and will be retained by Cell Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
| Dated: April 20, 2012 | By: | /s/ James A. Bianco, M.D | ||
| James A. Bianco, M.D. | ||||
| Chief Executive Officer |
I, Louis A. Bianco, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of Cell Therapeutics, Inc., that, to my knowledge, the Quarterly Report of Cell Therapeutics, Inc. on Form 10-Q for the fiscal quarter ended March 31, 2012 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of Cell Therapeutics, Inc.
A signed original of this written statement required by Section 906 has been provided to Cell Therapeutics, Inc. and will be retained by Cell Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
| Dated: April 20, 2012 | By: | /s/ Louis A. Bianco | ||
| Louis A. Bianco | ||||
| Executive Vice President, Finance and Administration |